본문으로 건너뛰기
← 뒤로

Cytoreductive Radical Prostatectomy in Men with De Novo Metastatic Prostate Cancer.

2/5 보강
The Urologic clinics of North America 📖 저널 OA 2.3% 2022: 0/1 OA 2024: 0/1 OA 2025: 0/3 OA 2026: 0/32 OA 2022~2026 2026 Vol.53(2) p. 273-283 Prostate Cancer Treatment and Resear
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-04-29
OpenAlex 토픽 · Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Urologic and reproductive health conditions

Ragam R, Chua KJ, Wei J, Aron M

📝 환자 설명용 한 줄

Cytoreductive radical prostatectomy (CRP) involves removing the primary tumor in men with de novo metastatic prostate cancer, particularly those with resectable primary, good response to systemic ther

이 논문을 인용하기

↓ .bib ↓ .ris
APA Radhika Ragam, Kevin Joseph Chua, et al. (2026). Cytoreductive Radical Prostatectomy in Men with De Novo Metastatic Prostate Cancer.. The Urologic clinics of North America, 53(2), 273-283. https://doi.org/10.1016/j.ucl.2026.02.010
MLA Radhika Ragam, et al.. "Cytoreductive Radical Prostatectomy in Men with De Novo Metastatic Prostate Cancer.." The Urologic clinics of North America, vol. 53, no. 2, 2026, pp. 273-283.
PMID 41986023 ↗

Abstract

Cytoreductive radical prostatectomy (CRP) involves removing the primary tumor in men with de novo metastatic prostate cancer, particularly those with resectable primary, good response to systemic therapy, and good performance status. Emerging evidence suggests CRP may reduce tumor burden, enhance systemic therapy efficacy, and improve survival in select patients. Robot-assisted approaches are increasingly favored for their lower complication rates. CRP can better prevent local complications than radiotherapy but carries higher risks of incontinence and erectile dysfunction. CRP has been shown to be safe in early trials, and is currently being investigated in larger randomized studies to confirm its potential benefits.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반